The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Disclosures

Jennifer R. Brown, MD, PhD

Associate Professor of Medicine, Dana-Farber Cancer Institute

Received clinical research support/data safety monitoring board from Acerta Pharma, BeiGene, Eli Lilly and Company

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Acerta Pharma, BeiGene, Eli Lilly and Company, MEI Pharma, and Pfizer

 

David S. Ettinger, MD, FACP, FCCP

Alex Grass Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Served on scientific advisory board or as a consultant or expert witness for Alkemes, AstraZeneca Pharmaceuticals, BeyondSpring Pharmaceuticals, Bristol Myers Squibb, and Guardant Health

 

Thomas Flaig, MD

Professor, Medicine-Medical Oncology and Associate Dean for Clinical Research, School of Medicine, University of Colorado Cancer Center, Aurora

Was issued patent for work done as an employee of Aurora Oncology, University of Colorado

 

William J. Gradishar, MD

Director, Clinical Network; Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Received clinical research support/data safety monitoring board from Abbott Laboratories, Eli Lilly and Company, Genentech, Immunomedics, and Seattle Genetics

 

Robert I. Haddad, MD

Chief, Division of Head and Neck Oncology and Institute Physician, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School

Received clinical research support/data safety monitoring board from AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Genentech, Kura Oncology, Merck & Co, and Pfizer

Served on scientific advisory board or as a consultant or expert witness for AstraZeneca Pharmaceuticals, Aveo Pharmaceuticals, Bristol Myers Squibb, Celgene, Eisai, Genentech, GlaxoSmithKline, Kura Oncology, and Merck & Co

 

Gabriela Hobbs, MD

Clinical Director, Leukemia Service at Massachusetts General Hospital

Served on scientific advisory board or as a consultant or expert witness for Bristol Myers Squibb, Celgene, Constellation, Jazz Pharmaceuticals, and Novartis

 

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology (Division of Hematology), Mayo Clinic, Rochester, Minnesota

Served on scientific advisory board or as a consultant or expert witness for Argos Therapeutics, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, and Novartis

Has received personal compensation from Pharmacyclics, Cellectar and Karyopharm for serving on scientific advisory board or as a consultant

Involved in the development of Mayo Clinic mSMART guidelines

 

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from AbbVie, Allogene, Bristol Myers Squibb, Carsgen, Celgene, GlaxoSmithKline, MedImmune, Oncogene, Roche Laboratories, Takeda Pharmaceuticals North America, and Tenebio

Served on scientific advisory board or as a consultant or expert witness for AbbVie, BeiGene, Celgene, Cellectar, Oncopeptides, Roche Laboratories, and Takeda Pharmaceuticals North America

 

Karl D. Lewis, MD

Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine

Received clinical research support from or served on data safety monitoring board for Array, Bristol Myers Squibb, Incyte, Iovance, Kartos, Merck & Co, Nektar Therapeutics, Neon, Oncosec, Regeneron Pharmaceuticals, and Roche Laboratories

Served on scientific advisory board or as a consultant or expert witness for Genentech, Merck & Co, and Regeneron Pharmaceuticals

 

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board as principal investigator for Novartis

Served on scientific advisory board or as a consultant or expert witness for Bristol Myers Squibb, Novartis, Takeda Pharmaceuticals North America, and Pfizer

 

Rebecca Olin, MD, MS

Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Received clinical research support from or served on data safety monitoring board for Astellas Pharma US, AstraZeneca Pharmaceuticals, Daiichi Sankyo, Genentech, MedImmune, Mirati, Novartis, Pfizer, Spectrum Pharmaceuticals, Takeda Pharmaceuticals North America

Served on scientific advisory board or as a consultant or expert witness for Amgen and Genentech

 

Sandy Srinivas, MD

Professor of Medicine, Stanford University Medical Center

Received clinical research support from or served on a data safety monitoring board for AstraZeneca Pharmaceuticals, Bayer HealthCare, Bristol Myers Squibb, Clovis Oncology, Eisai, Exelixis, Genentech, Merck &  Co, Pfizer, Seattle Genetics, and Tracon Pharmaceuticals

Served on scientific advisory board or as a consultant or expert witness for Bayer HealthCare, Eisai, Genentech, Janssen Pharmaceutica Products, and Merck & Co

 

Theresa L. Werner, MD

Medical Director, Clinical Trials Office; Associate Professor of Medicine, Oncology Division, Huntsman Cancer Institute, University of Utah, Salt Lake City

Reported no conflicts of interest

 

Medical Writers:

The following medical writers reported no conflicts of interest.

Cordi Craig; Joseph Cupolo; Celeste L. Dixon;  Dana A. Elya, MS, RD, CDN; Joseph Fanelli; Julia Fiederlein; Melissa E. Fryman, MS; Lauren Harrison, MS; Kelly M. Hennessey, PhD; Nahae Kim, MPH; Susan London; Margie Miller; Anna Nowogrodzki; Hillary Ojeda; Susan Reckling; Kayci Reyer; Max J. Rosenthal; Jocelyn Solis-Moreira, MS; Melissa Steele-Ogus; Joshua Swore and Sara Tewksbury

Sarah Campen, PharmD: Her spouse works for Johnson & Johnson/Janssen.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.